<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04039555</url>
  </required_header>
  <id_info>
    <org_study_id>COER</org_study_id>
    <nct_id>NCT04039555</nct_id>
  </id_info>
  <brief_title>Clinical Study to Compare the Efficacy of Erbium-Yag Laser or CO2RE Intimate Laser With Sham (COER)</brief_title>
  <acronym>COER</acronym>
  <official_title>Clinical Study to Compare the Efficacy of 1 Series of 2 Treatment Sessions With Erbium-Yag Laser or CO2RE Intimate Laser vs Sham (Sham Treatment) for Vulvovaginal Atrophy (Dryness and / or Dyspareunia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Palacios</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Palacios</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial compares the efficacy of two different laser treatments for vaginal atrophy
      symptoms between them and with sham treatment. Patients will be randomized to one of the two
      lasers or sham treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients over 45 years of age with one or more AVV symptoms who wish to participate in the
      study will be included, 2 laser sessions spaced one of another 4-6 weeks, and final tracking
      visit 4-6 weeks of the last laser session.

      Each patient shall be randomly assigned an arm of tto, with laser CO2, or laser Erbium, or
      sham group
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 24, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>It is a single blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Comparation of 1 series of 2 treatment sessions with Erbium-Yag or intimate CO2RE vs Sham for the symptoms of vulvovaginal atrophy</measure>
    <time_frame>Visit 1(Day 0), visit 2(5 +/-1 weeks), visit 3(10 +/-1 weeks)</time_frame>
    <description>Analyzing the differences in % the cytological maturity index, changes in the intensity of symptoms and PH range of normality (3,5- 4.5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences between CO2RE and Erbium-Yag</measure>
    <time_frame>Visit 1(Day 0), visit 2(5 +/-1 weeks), visit 3(10 +/-1 weeks)</time_frame>
    <description>Analyzing the differences in % the cytological maturity index, changes in the intensity of symptoms and PH range of normality (3,5- 4.5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Vulvar and Vaginal Health Index (VVHI)</measure>
    <time_frame>Visit 1(Day 0), visit 2(5 +/-1 weeks), visit 3(10 +/-1 weeks)</time_frame>
    <description>Analyzing the information registered in the visits performed</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Vaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>Active Arm - CO2 intimate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 2 sessions of CO2 laser treatment, spaced 4 to 6 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Arm - Erbium-yag</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 2 sessions of Erbium-Yag laser treatment, spaced 4 to 6 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive 2 sessions of Erbium-Yag laser or CO2 laser treatment with non-therapeutic energy, spaced between 4 and 6 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CO2 intimate</intervention_name>
    <description>Two sessions with CO2 intimate laser for vaginal symptoms treatment</description>
    <arm_group_label>Active Arm - CO2 intimate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Erbium-yag</intervention_name>
    <description>Two sessions with Erbium-yag laser for vaginal symptoms treatment</description>
    <arm_group_label>Active Arm - Erbium-yag</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CO2 intimate or Erbium-yag</intervention_name>
    <description>Two sessions of one of the two lasers with no therapeuthical energy</description>
    <arm_group_label>Sham Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women older than 45 years with at least one year of amenorrhea and at least one
             symptom of vulvovaginal atrophy of moderate and / or severe intensity.

        Exclusion Criteria:

          -  Hormone treatment in the last three months for vulvovaginal atrophy

          -  Treatment with vaginal moisturizers in the last week for vulvovaginal atrophy

          -  Laser treatment in the last 12 months.

          -  Acute and recurrent infections of the urinary tract in the last 3 months.

          -  Acute genital infections

          -  Vaginal prolapse

          -  Alterations in the area to be treated, such as lacerations, abrasions or ulcers (time
             of resolution at medical discretion)

          -  Chronic decompensated noncommunicable diseases

          -  Women who are pregnant or have given birth in the last 3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Santiago Palacios, PhD</last_name>
    <phone>+34 91 578 05 17</phone>
    <email>ipalacios@institutopalacios.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Soler, SC</last_name>
    <phone>+34 91 578 05 17</phone>
    <email>eva.maria.soler@institutopalacios.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Palacios</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

